With differentiated pharmacokinetics compared to other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.īRUKINSA is supported by a broad clinical program which includes more than 4,700 subjects in 35 trials in more than 25 countries and regions. BRUKINSA was specifically designed to deliver targeted and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. "I'm proud to bring this potentially best-in-class medicine to Brazil and look forward to working with our partner, Adium on commercialization activities."īRUKINSA (zanubrutinib) is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. These approvals demonstrate our commitment to accelerate development and broaden access to innovative medicines around the globe," said Alex Carvalho, Country General Manager, Brazil, at BeiGene. "We have carried out an expansive and global clinical development program for our innovative BTK inhibitor, BRUKINSA, which has led to approval for the treatment of WM, MZL, and MCL in Brazil. BeiGene is focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide. BRUKINSA was previously approved as a treatment in Brazil for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. BRUKINSA now approved in Brazil for three indicationsīeiGene, (NASDAQ: BGNE HKEX: 06160 SSE: 688235), a global biotechnology, today announced BRUKINSA (zanubrutinib) has been approved in Brazil for the treatment of adult patients with Waldenström's macroglobulinemia (WM) and adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
0 Comments
Leave a Reply. |